Ptc Therapeutics Announces Results From The Phase 2 Pivot-Hd Study of PTC518 In Stage 2 And Stage 3 Huntington's Disease Patients Study Met Its Primary Endpoint of Reduction in Blood Huntingtin Protein Levels At Week 12 And Favorable Safety and Tolerabili